Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Lexaria Bioscience Corp. (LEXX : NSDQ)
 
 • Company Description   
Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. Lexaria Bioscience Corp. is based in Kelowna, Canada.

Number of Employees: 6

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.15 Daily Weekly Monthly
20 Day Moving Average: 91,971 shares
Shares Outstanding: 5.95 (millions)
Market Capitalization: $12.80 (millions)
Beta: 1.26
52 Week High: $8.48
52 Week Low: $1.92
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -34.85% -26.62%
12 Week -36.76% -30.48%
Year To Date -46.65% -34.81%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
100 - 740 MCCURDY ROAD
-
KELOWNA,A1 V1X 2P7
CAN
ph: 250-765-6424
fax: -
info@lexariabioscience.com http://www.lexariabioscience.com
 
 • General Corporate Information   
Officers
Christopher Bunka - Chief Executive Officer and Chairman
John Docherty - President
Gregory Downey - Chief Financial Officer
Ted McKechnie - Director
Nicholas Baxter - Director

Peer Information
Lexaria Bioscience Corp. (CORR.)
Lexaria Bioscience Corp. (RSPI)
Lexaria Bioscience Corp. (CGXP)
Lexaria Bioscience Corp. (BGEN)
Lexaria Bioscience Corp. (GTBP)
Lexaria Bioscience Corp. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 52886N406
SIC: 2834
Fiscal Year
Fiscal Year End: August
Last Reported Quarter: 02/01/22
Next Expected EPS Date: 07/21/22
Share - Related Items
Shares Outstanding: 5.95
Most Recent Split Date: 1.00 (0.03:1)
Beta: 1.26
Market Capitalization: $12.80 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.09 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/21/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.14
Price/Cash Flow: -
Price / Sales: 45.70
EPS Growth
vs. Year Ago Period: 10.71%
vs. Previous Quarter: 28.57%
Sales Growth
vs. Year Ago Period: -83.85%
vs. Previous Quarter: 121.43%
ROE
02/28/22 - -63.35
11/30/21 - -59.83
08/31/21 - -61.45
ROA
02/28/22 - -62.06
11/30/21 - -58.29
08/31/21 - -59.35
Current Ratio
02/28/22 - 63.86
11/30/21 - 45.80
08/31/21 - 81.18
Quick Ratio
02/28/22 - 63.67
11/30/21 - 45.69
08/31/21 - 80.98
Operating Margin
02/28/22 - -2,602.91
11/30/21 - -1,577.35
08/31/21 - -783.13
Net Margin
02/28/22 - -2,555.05
11/30/21 - -1,207.27
08/31/21 - -556.99
Pre-Tax Margin
02/28/22 - -2,614.70
11/30/21 - -1,236.75
08/31/21 - -575.93
Book Value
02/28/22 - 1.89
11/30/21 - 2.00
08/31/21 - 2.56
Inventory Turnover
02/28/22 - 2.63
11/30/21 - 1.90
08/31/21 - 2.04
Debt-to-Equity
02/28/22 - 0.00
11/30/21 - 0.00
08/31/21 - 0.00
Debt-to-Capital
02/28/22 - 0.00
11/30/21 - 0.00
08/31/21 - 0.00
 

Powered by Zacks Investment Research ©